This podcast was initiated and funded by Bayer Australia Ltd. The introduction of second-generation androgen-receptor inhibitors has altered the treatment paradigm for non-metastatic castrate-resistant prostate cancer (nmCRPC). In this podcast the limbic speaks to Doctor Neal Shore from the Carolina Urologic Research Centre in the United States and local oncologist Doctor Laurence Krieger from the ...
Podcast: Patient-physician decision making in the management of nmCRPC
6 Apr 2021
Sponsored by Bayer Australia Limited